Key Insights

Highlights

Success Rate

91% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 17/100

Termination Rate

6.1%

2 terminated out of 33 trials

Success Rate

90.9%

+4.4% vs benchmark

Late-Stage Pipeline

30%

10 trials in Phase 3/4

Results Transparency

40%

8 of 20 completed with results

Key Signals

8 with results91% success

Data Visualizations

Phase Distribution

26Total
Not Applicable (8)
P 1 (2)
P 2 (6)
P 3 (7)
P 4 (3)

Trial Status

Completed20
Recruiting5
Active Not Recruiting3
Terminated2
Not Yet Recruiting1
Enrolling By Invitation1

Trial Success Rate

90.9%

Benchmark: 86.5%

Based on 20 completed trials

Clinical Trials (33)

Showing 20 of 20 trials
NCT05193552Phase 4RecruitingPrimary

Usage of Spirometry in Managing IgG Therapy in CVID With Airway Disease

NCT04339777Phase 2Recruiting

Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity

NCT06145100Completed

Prediction of Portal Hypertension in Patients With CVID (CVID-pHT)

NCT02579967Phase 2Recruiting

Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies

NCT00943514Recruiting

Natural History of Bronchiectasis

NCT03663933Phase 2Active Not Recruiting

Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation

NCT01652092Not ApplicableActive Not Recruiting

Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies

NCT05593588Phase 2Enrolling By InvitationPrimary

Senolytics Treatment of Interstitial Lung Disease in Common Variable Immunodeficiency

NCT06355323Not ApplicableCompleted

Bronchiectasis Prevalence in Patients With Primary Humoral Immunodefiency in Champagne-Ardenne Region, France

NCT07255157Not ApplicableNot Yet RecruitingPrimary

Peripheral Helper T-cells in Common Variable ImmunoDeficiency

NCT04925375Phase 2Recruiting

Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease

NCT05321407Active Not Recruiting

COVID-19 Vaccine Responses in PIDD Subjects

NCT01196702CompletedPrimary

Lymphocyte Immunophenotyping in Common Variable Immunodeficiency

NCT03513328Phase 1Completed

Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation

NCT05481554UnknownPrimary

Composition and Function of Gut Microbiota in Porto-sinusoidal Vascular Disease Associated With Variable Common Immunodeficiency

NCT03188419Completed

Breadth of Donor Options for People With Inherited Diseases Requiring Allogeneic Hematopoietic Stem Cell Transplant in the Era of Alternative Donor Transplants Using Post-Transplantation Cyclophosphamide

NCT00015431CompletedPrimary

Immune System and Gut Abnormalities in Patients With Common Variable Immunodeficiency With and Without Gastrointestinal Symptoms

NCT01884311Phase 3Completed

Pharmacokinetics (PK) and Safety of Subgam-VF in Primary Immunodeficiency Diseases

NCT03211689Not ApplicableCompleted

The Impact of Exercise on Stress, Fatigue, and Quality of Life in Individuals With Primary Immunodeficiency Disease

NCT03534479Not ApplicableCompletedPrimary

Human IgGs and Endothelial Function in Vivo in Humans

Scroll to load more

Research Network

Activity Timeline